scholarly journals Transferrin Receptor (TFRC): A Potential Biomarker for The Diagnosis and Prognosis of Sepsis

2021 ◽  
Author(s):  
lin fang li ◽  
Yao liu ◽  
mu hu chen ◽  
ying chun hu
Keyword(s):  
Survival Analysis ◽  
Meta Analysis ◽  
Roc Curves ◽  
Sepsis Group ◽  
Prognostic Performance ◽  
Go Annotation ◽  
Diagnosis And Prognosis ◽  
Potential Biomarker ◽  
Differential Proteins ◽  
Candidate Protein

Abstract Objective This study applies the data independent acquisition (DIA) technique combined with bioinformatics to identify differential proteins in sepsis patients and performed ELISA method to validate the candidate protein of clinical value, in an attempt to find new biomarkers for the diagnosis and prognosis of sepsis. Methods Blood samples from sepsis patients (Sepsis group, n = 50) and healthy individuals (NC group, n = 10) were collected from Affiliated Hospital of Southwest Medical University. Mass spectrometry analysis was designed for 22 sepsis samples (randomly selected) and 10 healthy controls by DIA method, and the obtained differential proteins were subjected to GO annotation, meta-analysis and survival analysis to identify the candidate biomarker protein. ELISA was applied to validate the protein expression in original cohorts. ROC curves based on ELISA data were plotted to discuss the diagnostic and prognostic performance of the candidate protein and several clinical indexes, including C-reactive protein (CRP), procalcitonin (PCT) and lactate (Lac). Results DIA data showed that there were 142 differential proteins in the Sepsis group versus the NC group, comprising 36 down-regulated and 106 up-regulated. GO annotation revealed that the differential proteins were significantly enriched in the biological functions involved in immune response, response to stress, inflammatory response, and cell activation. The top 11 proteins with the greatest difference were found according to the p-values in DIA (FUCO2, MGAT1, OAF, AACT, TFRC, CCL14, EXTL2, KLKB1, TETN,CRP,SAA1). Meta-analysis identified significant differential expression of TFRC in the NC versus Sepsis and in the Survival versus Non-survival groups based on GEO database. Survival analysis revealed that the low expression of TFRC indicated a higher survival rate in sepsis patients. ELISA found TFRC concentration in collected clinical samples were significant differential in the NC versus Sepsis and in the Survival versus Nonsurvival groups (p < 0.05). ROC curves gave an AUC of 0.790 for TFRC in distinguishing the normal individuals and sepsis patients, showing good diagnostic performance. Besides, the AUC for TFRC in distinguishing the survivors and deaths was 0.744, indicating good prognostic performance, which was superior to PCT, CRP and Lac. Conclusion This study identified TFRC through DIA, bioinformatics and ELISA analyses, which showed differential expression in sepsis patients as well as good diagnostic and prognostic value. TFRC is expected to be a potential biomarker for sepsis.

scholarly journals The value of miR-155 as a biomarker for the diagnosis and prognosis of lung cancer: a systematic review with meta-analysis

2019 ◽  
Author(s):  
Chuchu Shao ◽  
Fengming Yang ◽  
Zhiqiang Qin ◽  
Xinming Jing ◽  
Yongqian Shu ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Systematic Review ◽  
Likelihood Ratio ◽  
Meta Analysis ◽  
Positive Likelihood Ratio ◽  
Disease Free Survival ◽  
Negative Likelihood Ratio ◽  
Free Survival ◽  
Diagnosis And Prognosis ◽  
Potential Biomarker

Abstract Background: Recently, a growing number of studies have reported the coorelation between miR-155 and the diagnosis and prognosis of lung cancer, but results of these researches were still controversial due to insufficient sample size. Thus, we carried out the systematic review and meta-analysis to figure out whether miR-155 could be a screening tool in the detection and prognosis of lung cancer. Methods: A meta-analysis of 13 articles with 19 studies was performed by retrieving the PubMed, Embase and Web of Science. We screened all correlated literaters until December 1st, 2018. For the diagnosis analysis of miR-155 in lung cancer, sensitivity(SEN), specificity (SPE), positive likelihood ratio (PLR), negative likelihood ratio (NLR), diagnostic odds ratio (DOR) and area under the ROC curve (AUC) were pooled to evaluate the accuracy of miRNA-155 in the diagnosis of lung cancer. For the prognosis analysis of miR-155 in lung cancer, the pooled HRs and 95% CIs of miR-155 for overall survival/disease free survival/progression-free survival (OS/DFS/PFS) were calculated. In addition, Subgroup and meta-regression analyses were performed to distinguish the potential sources of heterogeneity between studies. Results: For the diagnostic analysis of miR-155 in lung cancer, the pooled SEN and SPE were 0.82 (95% CI: 0.72-0.88) and 0.78 (95% CI: 0.71-0.84), respectively. Besides, the pooled PLR was 3.75 (95% CI: 2.76-5.10), NLR was 0.23 (95% CI: 0.15-0.37), DOR was 15.99 (95% CI: 8.11-31.52) and AUC was 0.87 (95% CI: 0.84-0.90), indicating a significant value of miR-155 in the lung cancer detection. For the prognostic analysis of miR-155 in lung cancer, up-regulated miRNA-155 expression was not significantly associated with a poor OS (pooled HR = 1.26, 95% CI: 0.66-2.40) or DFS/PFS (pooled HR = 1.28, 95% CI: 0.82-1.97). Conclusions: The present meta-analysis demonstrated that miR-155 could be a potential biomarker for the detection of lung cancer but not an effective biomarker for predicting the outcomes of lung cancer. Furthermore, more well-designed researches with larger cohorts were warranted to confirm the value of miR-155 for the diagnosis and prognosis of lung cancer.

scholarly journals The value of miR-155 as a biomarker for the diagnosis and prognosis of lung cancer: a systematic review with meta-analysis

2019 ◽  
Author(s):  
Chuchu Shao ◽  
Fengming Yang ◽  
Zhiqiang Qin ◽  
Xinming Jing ◽  
Yongqian Shu ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Systematic Review ◽  
Likelihood Ratio ◽  
Meta Analysis ◽  
Positive Likelihood Ratio ◽  
Disease Free Survival ◽  
Negative Likelihood Ratio ◽  
Free Survival ◽  
Diagnosis And Prognosis ◽  
Potential Biomarker

Abstract Background: Recently, a growing number of studies have reported the coorelation between miR-155 and the diagnosis and prognosis of lung cancer, but results of these researches were still controversial due to insufficient sample size. Thus, we carried out the systematic review and meta-analysis to figure out whether miR-155 could be a screening tool in the detection and prognosis of lung cancer. Methods: A meta-analysis of 13 articles with 19 studies was performed by retrieving the PubMed, Embase and Web of Science. We screened all correlated literaters until December 1st, 2018. For the diagnosis analysis of miR-155 in lung cancer, sensitivity(SEN), specificity (SPE), positive likelihood ratio (PLR), negative likelihood ratio (NLR), diagnostic odds ratio (DOR) and area under the ROC curve (AUC) were pooled to evaluate the accuracy of miRNA-155 in the diagnosis of lung cancer. For the prognosis analysis of miR-155 in lung cancer, the pooled HRs and 95% CIs of miR-155 for overall survival/disease free survival/progression-free survival (OS/DFS/PFS) were calculated. In addition, Subgroup and meta-regression analyses were performed to distinguish the potential sources of heterogeneity between studies. Results: For the diagnostic analysis of miR-155 in lung cancer, the pooled SEN and SPE were 0.82 (95% CI: 0.72-0.88) and 0.78 (95% CI: 0.71-0.84), respectively. Besides, the pooled PLR was 3.75 (95% CI: 2.76-5.10), NLR was 0.23 (95% CI: 0.15-0.37), DOR was 15.99 (95% CI: 8.11-31.52) and AUC was 0.87 (95% CI: 0.84-0.90), indicating a significant value of miR-155 in the lung cancer detection. For the prognostic analysis of miR-155 in lung cancer, up-regulated miRNA-155 expression was not significantly associated with a poor OS (pooled HR = 1.26, 95% CI: 0.66-2.40) or DFS/PFS (pooled HR = 1.28, 95% CI: 0.82-1.97). Conclusions: The present meta-analysis demonstrated that miR-155 could be a potential biomarker for the detection of lung cancer but not an effective biomarker for predicting the outcomes of lung cancer. Furthermore, more well-designed researches with larger cohorts were warranted to confirm the value of miR-155 for the diagnosis and prognosis of lung cancer.

scholarly journals The value of miR-155 as a biomarker for the diagnosis and prognosis of lung cancer: a systematic review with meta-analysis

2019 ◽  
Author(s):  
Chuchu Shao ◽  
Fengming Yang ◽  
Zhiqiang Qin ◽  
Xinming Jing ◽  
Yongqian Shu ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Systematic Review ◽  
Meta Analysis ◽  
Diagnostic Value ◽  
Bibliographic Databases ◽  
Diagnosis And Prognosis ◽  
Prognostic Analysis ◽  
Potential Biomarker ◽  
Keywords Lung Cancer ◽  
The Impact

Abstract Abstract Background: In recent years, several studies have investigated the impact of miR-155 on the diagnosis and prognosis of LCa, but results of these researches were still controversial due to insufficient sample size. Thus, we carried out this systematic review and meta-analysis to figure out whether miR-155 could be a screening tool in the detection and prognosis of LCa. Methods: A meta-analysis of 13 articles with 19 studies was performed by retrieving the PubMed, Embase and other bibliographic databases. We screened all correlated literaters until December 1st, 2018. For the diagnostic value of miR-155 in LCa, SEN, SPE, PLR, NLR, DOR and AUC were pooled to evaluate the accuracy of miRNA-155 in the diagnosis of LCa. Subgroup and meta-regression analyses were performed to distinguish the potential sources of heterogeneity between studies. For the prognositic value of miR-155 in LCa, the pooled HRs and 95% CIs of miRNA-155 for OS and DFS/ PFS were calculated. Results: For the diagnosis analysis of miR-155 in LCa, the pooled SEN and SPE were 0.82 (95% CI: 0.72-0.88) and 0.78 (95% CI: 0.71-0.84), respectively. Besides, the pooled PLR was 3.75 (95% CI: 2.76-5.10), NLR was 0.23 (95% CI: 0.15-0.37), DOR was 15.99 (95% CI: 8.11-31.52) and AUC was 0.87 (95% CI: 0.84-0.90), indicating a significant value of miR-155 in the LCa detection. For the prognostic analysis of miR-155 in LCa, up-regulated miRNA-155 expression was not significantly associated with a poor OS (pooled HR = 1.26, 95% CI: 0.66-2.40) or DFS/PFS (pooled HR = 1.28, 95% CI: 0.82-1.97). Conclusions: This meta-analysis demonstrated that miR-155 could be used as a potential biomarker in the diagnosis of LCa but not an effective biomarker for predicting the prognosis of LCa. Furthermore, more well-designed researches with larger cohorts were warranted to confirm the value of miR-155 for the diagnosis and prognosis of LCa. Keywords: lung cancer, miR-155, diagnosis, prognosis, biomarker

scholarly journals Presepsin: A potential biomarker of PJI? A comparative analysis with known and new infection biomarkers

2017 ◽  
Vol 31 ◽  
pp. 039463201774935 ◽  
Author(s):  
Monica Gioia Marazzi ◽  
Filippo Randelli ◽  
Marco Brioschi ◽  
Lorenzo Drago ◽  
Carlo Luca Romanò ◽  
...  
Keyword(s):  
Inflammatory Responses ◽  
Joint Infection ◽  
Area Under The Curve ◽  
Roc Curves ◽  
Diagnostic Value ◽  
Reactive Protein ◽  
Diagnosis And Prognosis ◽  
Diagnostic Potential ◽  
Potential Biomarker ◽  
No Gold Standard

There is still no “gold standard” for the diagnosis and prognosis of post-operative periprosthetic joint infection (PJI). Among serum biomarkers, an emerging molecule is presepsin, the soluble fraction of CD14, recently described in other settings as a powerful diagnostic tool to detect sepsis at different degrees of severity. The aim of this study was to investigate the diagnostic and prognostic value of presepsin in PJI. A total of 30 patients with PJI and 30 patients without PJI were enrolled. Presepsin, C-reactive protein (CRP), serum interleukin (IL)-6, triggering receptor expressed on myeloid cells 1 (TREM-1), CCL2, matrix metalloproteinase 9 (MMP-9), CD163, osteopontin (OPN), and toll-like receptor 2 (TLR2) were measured at different times after surgery. Receiver operating characteristic (ROC) curves and area under the curve (AUC) were analyzed for each biomarker. Presepsin showed greater diagnostic value than CRP and IL-6; CD163, TREM-1, and MMP-9 had very low diagnostic potential. Presepsin, OPN, CCL2, suPAR, and TLR2 all decreased significantly with increasing time of recovery after surgery in PJI patients. Presepsin can be considered a useful tool for the diagnosis and clinical monitoring of PJI and can be backed by a panel of new inflammatory markers involved in monocyte-/macrophage-mediated inflammatory responses, such as OPN, CCL2, TLR2, and suPAR.

scholarly journals The value of miR-155 as a biomarker for the diagnosis and prognosis of lung cancer: a systematic review with meta-analysis

BMC Cancer ◽  
2019 ◽  
Vol 19 (1) ◽  
Author(s):  
Chuchu Shao ◽  
Fengming Yang ◽  
Zhiqiang Qin ◽  
Xinming Jing ◽  
Yongqian Shu ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Systematic Review ◽  
Likelihood Ratio ◽  
Meta Analysis ◽  
Positive Likelihood Ratio ◽  
Disease Free Survival ◽  
Negative Likelihood Ratio ◽  
Free Survival ◽  
Diagnosis And Prognosis ◽  
Potential Biomarker

Abstract Background Recently, a growing number of studies have reported the coorelation between miR-155 and the diagnosis and prognosis of lung cancer, but results of these researches were still controversial due to insufficient sample size. Thus, we carried out the systematic review and meta-analysis to figure out whether miR-155 could be a screening tool in the detection and prognosis of lung cancer. Methods A meta-analysis of 13 articles with 19 studies was performed by retrieving the PubMed, Embase and Web of Science. We screened all correlated literaters until December 1st, 2018. For the diagnosis analysis of miR-155 in lung cancer, sensitivity (SEN), specificity (SPE), positive likelihood ratio (PLR), negative likelihood ratio (NLR), diagnostic odds ratio (DOR) and area under the ROC curve (AUC) were pooled to evaluate the accuracy of miRNA-155 in the diagnosis of lung cancer. For the prognosis analysis of miR-155 in lung cancer, the pooled HRs and 95% CIs of miR-155 for overall survival/disease free survival/progression-free survival (OS/DFS/PFS) were calculated. In addition, Subgroup and meta-regression analyses were performed to distinguish the potential sources of heterogeneity between studies. Results For the diagnostic analysis of miR-155 in lung cancer, the pooled SEN and SPE were 0.82 (95% CI: 0.72–0.88) and 0.78 (95% CI: 0.71–0.84), respectively. Besides, the pooled PLR was 3.75 (95% CI: 2.76–5.10), NLR was 0.23 (95% CI: 0.15–0.37), DOR was 15.99 (95% CI: 8.11–31.52) and AUC was 0.87 (95% CI: 0.84–0.90), indicating a significant value of miR-155 in the lung cancer detection. For the prognostic analysis of miR-155 in lung cancer, up-regulated miRNA-155 expression was not significantly associated with a poor OS (pooled HR = 1.26, 95% CI: 0.66–2.40) or DFS/PFS (pooled HR = 1.28, 95% CI: 0.82–1.97). Conclusions The present meta-analysis demonstrated that miR-155 could be a potential biomarker for the detection of lung cancer but not an effective biomarker for predicting the outcomes of lung cancer. Furthermore, more well-designed researches with larger cohorts were warranted to confirm the value of miR-155 for the diagnosis and prognosis of lung cancer.

scholarly journals Identification of abnormally high expression of POGZ as a new biomarker associated with a poor prognosis in osteosarcoma

2021 ◽  
Vol 65 (3) ◽  
Author(s):  
Sikuan Zheng ◽  
Yue Liu ◽  
Haohe Sun ◽  
Jingyu Jia ◽  
Tianlong Wu ◽  
...  
Keyword(s):  
Survival Analysis ◽  
Poor Prognosis ◽  
Cell Model ◽  
Meta Analysis ◽  
High Expression ◽  
Clinical Samples ◽  
Invasion And Migration ◽  
Potential Biomarker ◽  
A Cell ◽  
And Migration

Osteosarcoma (OS) is the most prevalent malignant bone tumor in children and young adults. There is an urgent need for a novel biomarker related to the prognosis of OS. We performed a meta-analysis incorporating six independent datasets and performed a survival analysis with one independent dataset GSE21257 in the GEO database for gene screening. The results revealed that one potential biomarker related to OS survival, POGZ was the most significantly upregulated gene. We also verified that the POGZ was overexpressed in clinical samples. The survival analysis revealed that POGZ is associated with a poor prognosis in OS. Moreover, flow cytometry analysis of isolated OS cells demonstrated that OS cells were arrested in the G1 phase after POGZ knockdown. The RNA-seq results indicated that POGZ was co-expressed with CCNE1 and CCNB1. Pathway analysis showed that genes associated with high expression levels of POGZ were related to the cell cycle pathway. A cell model was constructed to detect the effects of POGZ. After POGZ knockdown, OS cell proliferation, invasion and migration were all decreased. Therefore, POGZ is an important gene for evaluating the prognosis of OS patients and is a potential therapeutic target.

scholarly journals The diagnostic and prognostic value of miR-92a in gastric cancer: A systematic review and meta-analysis

Open Medicine ◽  
2021 ◽  
Vol 16 (1) ◽  
pp. 1386-1394
Author(s):  
Hanxu Guo ◽  
Yuhang Wang ◽  
Zhicheng Wang ◽  
Zishu Wang ◽  
Sheng Xue
Keyword(s):  
Gastric Cancer ◽  
Meta Analysis ◽  
Diagnostic Odds Ratio ◽  
Likelihood Ratios ◽  
Diagnosis And Prognosis ◽  
Prognostic Analysis ◽  
Knowledge Infrastructure ◽  
Hazard Ratios ◽  
Potential Biomarker ◽  
Gastric Cancer Patients

Abstract Background miR-92a is believed to have a significant role in the diagnosis and prognosis of different types of tumors, but the potential impact of its expression is still controversial due to the sample size. We conducted the meta-analysis to figure out whether miR-92a could be used as a detecting tool for assessing the prognosis of gastric cancer. Method A literature search was conducted by retrieving the Web of Science, PubMed, EMBASE, Chinese National Knowledge Infrastructure, VIP (Technology of Chongqing databases), and Wanfang databases (last updated by February 2020). The sensitivity (SEN), specificity (SPE), positive and negative likelihood ratios (PLR and NLR), diagnostic odds ratio (DOR), and area under the ROC curve (AUC) were pooled to explore the diagnostic performance of miR-92a. The pooled hazard ratios (HRs) and 95% CIs of miR-92a for overall survival (OS) were calculated to explore the prognostic performance of miR-92a. Results Nine articles containing 11 studies were included. The pooled SEN and SPE were 0.76 and 0.79. Besides, the pooled PLR and NLR were 3.7 and 0.30, and the pooled DOR was 12. AUC was 0.84, indicating a significant value of miR-92a in gastric cancer detection. For the prognostic analysis of miR-92a in gastric cancer, the univariate and multivariate data’s poor OS were 1.37 and 2.01. Conclusion The present meta-analysis demonstrated that miR-92a could be a potential biomarker for the detection of gastric cancer. miR-92a could also be used as a valuable indicator for predicting the prognosis of gastric cancer patients.

The miR-21 potential of serving as a biomarker for liver diseases in clinical practice

2020 ◽  
Vol 48 (5) ◽  
pp. 2295-2305
Author(s):  
Jiawei Zhang ◽  
Dandan Li ◽  
Rui Zhang ◽  
Peng Gao ◽  
Rongxue Peng ◽  
...  
Keyword(s):  
Clinical Practice ◽  
Liver Diseases ◽  
Hepatic Disease ◽  
Noninvasive Detection ◽  
Diagnosis And Prognosis ◽  
Expected Performance ◽  
Potential Biomarker ◽  
Disease Condition ◽  
Complex Regulatory Network

The role of miR-21 in the pathogenesis of various liver diseases, together with the possibility of detecting microRNA in the circulation, makes miR-21 a potential biomarker for noninvasive detection. In this review, we summarize the potential utility of extracellular miR-21 in the clinical management of hepatic disease patients and compared it with the current clinical practice. MiR-21 shows screening and prognostic value for liver cancer. In liver cirrhosis, miR-21 may serve as a biomarker for the differentiating diagnosis and prognosis. MiR-21 is also a potential biomarker for the severity of hepatitis. We elucidate the disease condition under which miR-21 testing can reach the expected performance. Though miR-21 is a key regulator of liver diseases, microRNAs coordinate with each other in the complex regulatory network. As a result, the performance of miR-21 is better when combined with other microRNAs or classical biomarkers under certain clinical circumstances.

Thiol/Disulfide Homeostasis as an Early Biomarker to Differentiate Sepsis from Pneumonia in Intensive Care Units

2020 ◽  
Vol 23 ◽  
Author(s):  
Esra Cakir ◽  
Gamze Gok ◽  
Ozcan Erel ◽  
Isil Ozkocak Turan
Keyword(s):  
Intensive Care Unit ◽  
Intensive Care ◽  
Early Period ◽  
Sepsis Group ◽  
Group Index ◽  
Total Thiol ◽  
Potential Biomarker ◽  
Early Biomarker ◽  
Index 2 ◽  
Research Period

Background: It is possible that patients with pneumonia also may have sepsis and the separation of these two clinical entities may induce some trouble to clinicians Objective: In order to separate a patient with pneumonia and a patient with sepsis, we qualify thiol/disulfide homeostasis as a potential biomarker. Method: This study designed between February 2018 – February 2019 prospectively. All patients in the intensive care unit with pneumonia and sepsis were enrolled in the study. At the time of hospitalization, thiol/disulfide homeostasis was measured. Patients diagnosed with sepsis and pneumonia were compared, in regards to thiol/disulfide homeostasis. Conclusion: In this study, we showed that thiol/disulfide homeostasis can be used as new markers in the early period in order to separate patients with sepsis and patients with pneumonia. Results: During research period, 103 patients with sepsis and 120 patients with pneumonia were enrolled into the study. When we compared native-thiol, total-thiol, and disulfide levels in both sepsis and pneumonia patients, we had similar results (p>0.05). In sepsis group, index-1 (disulfide/native thiol ratio) and index-2 (disulfide/total thiol ratio) were found out to be statistically higher than the pneumonia group, and index-3 (native thiol/total thiol ratio) was statistically lower than the pneumonia group (p=0.020, p= 0.021, p=0.021, respectively).

miR-224 is an early-stage biomarker of hepatocellular carcinoma with miR-224 and miR-125b as prognostic biomarkers

2020 ◽  
Vol 14 (15) ◽  
pp. 1485-1500
Author(s):  
Lichao Yang ◽  
Chunmeng Wei ◽  
Yasi Li ◽  
Xiao He ◽  
Min He
Keyword(s):  
Hepatocellular Carcinoma ◽  
Systematic Review ◽  
Survival Analysis ◽  
Sensitivity And Specificity ◽  
Poor Prognosis ◽  
Early Stage ◽  
Meta Analysis ◽  
Benign Lesion ◽  
Diagnostic Efficiency ◽  
Low Expression

Aim: The aim was to systematically investigate the miRNA biomarkers for early diagnosis of hepatocellular carcinoma (HCC). Materials & methods: A systematic review and meta-analysis of miRNA expression in HCC were performed. Results: A total of 4903 cases from 30 original studies were comprehensively analyzed. The sensitivity and specificity of miR-224 in discriminating early-stage HCC patients from benign lesion patients were 0.868 and 0.792, which were superior to α-fetoprotein. Combined miR-224 with α-fetoprotein, the sensitivity and specificity were increased to 0.882 and 0.808. Prognostic survival analysis showed low expression of miR-125b and high expression of miR-224 were associated with poor prognosis. Conclusion: miR-224 had a prominent diagnostic efficiency in early-stage HCC, with miR-224 and miR-125b being valuable in the prognostic diagnosis.

Sign in / Sign up

Export Citation Format

Share Document